Gómez-Acebo & Pombo has advised Grupo J. Uriach on the sale of its B2B business to investment fund MCH
The transaction has also counted on the participation of a group of investors. In this way, Uriach completes the process of divestment in the pharmaceutical sector and sale of generics, to focus on its strategic business plan in the consumer healthcare sector.
The divestment involves the sale of the two production plants owned by Grupo J. Uriach Group in Spain. On the one hand, the chemical plant (Urquima) located in Sant Fost de Campsentelles and the pharmaceutical plant in Palau-Solità i Plegamans, which currently allocates 75-80% of its production to the B2B business. The rest of this production is dedicated to CHC, which will continue to be made at this plant through a long-term strategic production agreement between Grupo J. Uriach and the new company owned by the new company. Grupo J. Uriach and the new company are owned by MCH. This area has a forecast turnover of €80 million by the end of 2021. MCH’s objective is to expand its activity through new developments and R&D investment.
The sale agreement is currently subject to the approval of the competition authorities.
Lazard has been the bank advisor leading the transaction and Deloitte has acted as financial advisor.
The GA_P´s team was formed by Corporate M&A partner and head of Gómez-Acebo & Pombo Barcelona office Daniel Marín (pictured left), along with lawyers Carolina Posse, Estefanía Fraile and Diana Urrego, Competition partner Iñigo Igartua (pictured centre) and associate Andrea Díez de Uré, Tax of counsel Núria Vila (pictured right), and Labour associate Begoña Vilar.